Carvedilol as a valuable hepatoprotective agent against methotrexate-induced damage chiefly due to its anti-oxidant inheritence

  • Mahwish Gul Department of Pharmacology, Ayub Medical College, Abbottabad, Pakistan
  • Muhammad Waqar Aslam Khan Department of Pharmacology & Therapeutics, Army Medical College, Rawalpindi, Pakistan
  • Syeda Urooj Zaidi Army Medical College, Rawalpindi, Pakistan
  • Sumetha Yaseen Army Medical College, Rawalpindi, Pakistan
  • Maryam Saqib Army Medical College, Rawalpindi, Pakistan
  • Muhammad Bilal Foundation University Medical College, Islamabad, Pakistan
Keywords: Methotrexate, Hepatotoxicity, Glutathione, Malondialdehyde, Anti-oxident, Carvedilol

Abstract

Background: Methotrexate is used in several heterogenic inflammatory and malignant disorders but life-sustaining liver organ is inevitably predisposed to damage by it. Carvedilol demonstrates anti-oxidant characteristic. The objective of this study was to explore the probable hepatic benefit it might provide when used concomitantly with methotrexate in rats. Methods: It was a laboratory-based randomized control trial done with collaborated effort of Pharmacology and Pathology Department, Army Medical College Rawalpindi along with National Institute of Health Islamabad, from March to July 2018. A total of 18 Sprague Dawley rats were randomly divided into 3 groups with 6 rats each. Untreated Group-I served as standard. On 7th and 14th day, 20 mg/Kg intraperitoneal methotrexate injection was given to rats in Group-II, while Group-III received carvedilol (10 mg/Kg/day) per-orally throughout with methotrexate intervention in-between. Blood was drawn for evaluation of liver function tests after giving chloroform anaesthesia on 15th day and later sacrificed for collection of liver samples for the assessment of histopathological changes and oxidative stress induction measured by glutathione and malondialdehyde levels. Results were analysed on SPSS-22 using independent t-test and one-way ANOVA for quantitative analysis and histological changes were interpreted via Chi-square test. Results: Methotrexate caused significant elevation of liver enzymes and histoarchitectural damage with concurrent glutathione depletion and malondialdehyde extension. Carvedilol brought significant fading of these detrimental changes. Conclusion: Carvedilol can cause attenuation of methotrexate-induced hepatotoxicity predominantly by its anti-oxidant quality thereby preserving the normal histoarchitecture as well as reducing deleterious alterations in liver enzymes, glutathione and malonaldehyde levels.

Author Biographies

Mahwish Gul, Department of Pharmacology, Ayub Medical College, Abbottabad, Pakistan

Department of Pharmacology, Ayub Medical College, Abbottabad-22040, Pakistan

Muhammad Waqar Aslam Khan, Department of Pharmacology & Therapeutics, Army Medical College, Rawalpindi, Pakistan

Head of Department of Pharmacology & Therapeutics, Army Medical College, Rawalpindi, Pakistan

Syeda Urooj Zaidi, Army Medical College, Rawalpindi, Pakistan

Department of Pharmacology & Therapeutics, Army Medical College, Rawalpindi, Pakistan

Sumetha Yaseen, Army Medical College, Rawalpindi, Pakistan

Department of Pharmacology & Therapeutics, Army Medical College, Rawalpindi, Pakistan

Maryam Saqib, Army Medical College, Rawalpindi, Pakistan

Army Medical College, Rawalpindi, Pakistan

Muhammad Bilal, Foundation University Medical College, Islamabad, Pakistan

Department of Accedent & Emergency, Quaid-e-Azam International Hospital, Islamabad, Pakistan

Downloads

Download data is not yet available.
Published
2019-06-30
How to Cite
1.
Gul M, Khan M, Zaidi S, Yaseen S, Saqib M, Bilal M. Carvedilol as a valuable hepatoprotective agent against methotrexate-induced damage chiefly due to its anti-oxidant inheritence. PJP [Internet]. 30Jun.2019 [cited 20Nov.2019];15(2):61-5. Available from: https://pjp.pps.org.pk/index.php/PJP/article/view/1132